Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Heart Failure with Reduced Ejection Fraction
NCT02653482Phase 4Completed
- Sponsor
- Saint Luke's Health System
- Start
- Mar 2016
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in heart failure with reduced ejection fraction (HFrEF), sponsored by Saint Luke's Health System. Started Mar 2016; status: completed.
02
Drugs
dapagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT02653482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02653482.